Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Influenza vaccine 2 LoA Report. The vaccine works by inducing the body's immune response.

Production 100

Production Vaccination Vaccine Immune Response 100

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Influenza vaccine 2 LoA Report. The vaccine works by inducing the body's immune response.

Production 100

Production Vaccination Vaccine Immune Response 100

Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. The authorisation allows the distribution of the vaccine in Scotland, Wales and England.

Vaccination 298

Vaccination Vaccine Protein Medicine 298

Bio Pharma Dive

DECEMBER 4, 2020

Moncef Slaoui, a leader of Operation Warp Speed, said he expects 100 million Americans to be vaccinated by the end of February — an ambitious target even as Moderna and Pfizer ramp up manufacturing.

Vaccination 250

Vaccination Vaccine Production Manufacturing 250

Pharmaceutical Technology

SEPTEMBER 7, 2022

Indian company Bharat Biotech International has secured approval from Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for its intranasal Covid-19 vaccine, iNCOVACC (BBV154), for usage in people aged 18 years and older. It is formulated to permit intranasal delivery via nasal drops.

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

Bio Pharma Dive

JULY 27, 2023

GSK expects its respiratory syncytial virus vaccine will be a multibillion dollar product. But at the beginning it’s predicting a slower launch than for its fast-selling shingles shot.

Vaccination 246

Vaccination Vaccine Production 246

Pharma Mirror

MAY 31, 2023

In the face of increasing global health challenges, the development and production of vaccines have become paramount. One critical aspect is the ability to scale up manufacturing processes to meet the growing demand for viral vector-based vaccines.

Vaccination 130

Vaccination Vaccine Manufacturing Production 130

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%

Vaccination 276

Vaccination Vaccine Development Clinical Trials 276

Pharmaceutical Technology

FEBRUARY 7, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]). The vaccine candidate has been approved for active immunisation against the infection in people from four years of age.

Vaccination 264

Vaccination Vaccine Genetics Trials 264

BioPharma Reporter

FEBRUARY 10, 2021

Three COVID-19 vaccine manufacturing sites are set to start production in France in the coming weeks: while the French government is seeking to boost further production with a â300m ($363m) initiative announced on Monday.

Production 128

Production Vaccination Vaccine Manufacturing 128

Pharmaceutical Technology

NOVEMBER 1, 2022

FEATURED COMPANIES COMMENDED : • Innovation • Product Launch • Safety VIEW PROFILE COMMENDED : • Business Expansion • Innovation • Investments VIEW PROFILE COMMENDED: • Social VIEW PROFILE. What are Product Launches? The Product Launches category recognises companies that have launched notable new products or services into the market.

Production 130

Production Marketing Manufacturing Vaccination 130

Bio Pharma Dive

OCTOBER 31, 2023

The pharma’s shot Abrysvo made over $300 million in sales during the first few months of its launch, and will be an important product to help offset declining COVID vaccine sales.

Vaccination 171

Vaccination Vaccine Sales Marketing 171

Bio Pharma Dive

AUGUST 26, 2022

The biotech claims its rivals’ vaccine Comirnaty, one of the world’s top-selling pharmaceutical products, infringes on two patents covering its messenger RNA technology.

Vaccination 256

Vaccination Vaccine RNA Production 256

XTalks

OCTOBER 28, 2021

BioNTech has announced plans to build a manufacturing facility in Africa to help ramp up production of COVID-19 mRNA vaccines for countries in the continent. With less than ten percent of its population vaccinated, Africa continues to be deeply affected by global vaccine inequities.

Vaccination 98

Vaccination Vaccine Production Manufacturing 98

Bio Pharma Dive

APRIL 5, 2021

The change, which follows the contractor's costly manufacturing mix-up, will displace production of AstraZeneca's unauthorized shot at the Baltimore site.

Production 236

Production Manufacturing Vaccination Vaccine 236

Bio Pharma Dive

SEPTEMBER 24, 2020

HHS Secretary Alex Azar said six vaccine developers involved with Operation Warp Speed had begun commercial manufacturing of their experimental shots.

Vaccination 226

Vaccination Vaccine Production Manufacturing 226

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

BioPharma Reporter

JANUARY 19, 2021

The European Commission has set out steps to ramp up production of COVID-19 vaccines; tackle issues in the supply chain; and boost vaccination campaigns.

Vaccination 111

Vaccination Vaccine Production Regulation 111

BioSpace

SEPTEMBER 12, 2023

The company plans to launch up to 15 new products and bring up to 50 new candidates to the clinic over the next five years as part of its growth plan, while scaling down COVID-19 manufacturing.

Production 115

Production Medicine Vaccination Vaccine 115

pharmaphorum

DECEMBER 4, 2020

Pfizer slashed its production targets for its COVID-19 vaccine because of a lack of raw materials for its supply chain, according to press reports. The big pharma has said in recent weeks that it expects to produce 50 million doses of the vaccine it developed with the German BioNTech, down from an earlier target of 100 million doses.

Vaccination 125

Vaccination Vaccine Production Regulation 125

BioSpace

SEPTEMBER 26, 2023

The COVID-19 pandemic highlighted a need for local production of vaccines. Now, German pharma company BioNTech has said it will start manufacturing vaccines in Africa.

Manufacturing 137

Manufacturing Vaccination Vaccine Pharma Companies 137

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccination 245

Vaccination Vaccine Development Allergies 245

Pharmaceutical Technology

AUGUST 2, 2022

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Following the demonstration at Samsung, the clinical trial of GreenLight’s Covid-19 booster vaccine is anticipated to commence this year.

Engineer 262

Engineer Vaccination Vaccine Clinical Trials 262

BioPharma Reporter

MARCH 31, 2021

Pfizer and BioNTech expect to expand COVID-19 vaccine manufacturing capacity to up to 2.5 billion doses by the end of 2021, thanks to the optimization of production processes and the recent initiation of production in Marburg, Germany.

Production 140

Production Vaccination Vaccine Manufacturing 140

Bio Pharma Dive

JULY 5, 2023

The vaccine has a chance to become Moderna’s second approved product and could help offset declining sales for its COVID-19 shot.

Vaccination 171

Vaccination Vaccine Regulation Sales 171

Bio Pharma Dive

JULY 25, 2022

Vaccine maker Bavarian Nordic said it is meeting demand for its shot with production capacity of 30 million doses a year.

Vaccination 265

Vaccination Vaccine Production 265

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Technology

AUGUST 1, 2022

Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222. The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates.

Vaccination 289

Vaccination Vaccine Gene Therapy RNA 289

Pharmaceutical Technology

NOVEMBER 24, 2022

South African bio-pharmaceutical firm Biovac and the International Vaccine Institute (IVI) in South Korea have signed a licencing and technology transfer agreement for developing and manufacturing an oral cholera vaccine (OCV).

Vaccination 147

Vaccination Vaccine Development Manufacturing 147

Pharmaceutical Technology

JULY 6, 2022

The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain.

Vaccination 264

Vaccination Vaccine Protein Clinical Trials 264

Medical Xpress

MARCH 1, 2023

The COVID-19 pandemic has highlighted the importance of vaccines in controlling infectious disease in sub-Saharan Africa and renewed interest in vaccine research and development across the continent.

Vaccination 97

Vaccination Vaccine Production Development 97

XTalks

MAY 27, 2021

To help boost production of its COVID-19 vaccine, Moderna has enlisted the services of Samsung Biologics , a contract development and manufacturing organization (CDMO) based in South Korea. The vaccine doses are intended for countries outside the US, with manufacturing planned to commence in the third quarter of 2021.

Manufacturing 98

Manufacturing Production Vaccination Vaccine 98

XTalks

FEBRUARY 21, 2022

BioNTech announced its new vaccine manufacturing approach in Africa where the company will ship modular factories, called the BioNTainer, to the continent to enable domestic production of the vaccines to help increase supplies. Related: BioNTech to Build First mRNA Vaccine Production Plant in Africa.

Vaccination 105

Vaccination Vaccine Production Manufacturing 105

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccination 195

Vaccination Vaccine Immune Response Bacteria 195

Pharmaceutical Technology

JUNE 24, 2022

Novavax has obtained emergency use authorization (EUA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), from the Taiwan Food and Drug Administration for use in people of the age 18 years and above. The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain.

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

Drug Discovery World

MAY 13, 2024

Reece Armstrong speaks to Melanie Adams-Cioaba , Senior Director and General Manager of pharma (cryo-EM), Thermo Fisher Scientific about advances in vaccine design. Using structural biology as central to vaccine design and development, and to drug discovery more generally, is what we mean by “rational design.”

Vaccination 59

Vaccination Vaccine Protein Antibody 59

Pharmaceutical Technology

FEBRUARY 21, 2023

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.

Sales 246

Sales Vaccination Vaccine Medicine 246